Q4 2019 13F Holders as of 31 Dec 2019
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
26,828,643
-
Number of holders
-
13
-
Total 13F shares, excl. options
-
2,623,150
-
Shares change
-
+345,620
-
Total reported value, excl. options
-
$18,886,000
-
Value change
-
+$2,667,626
-
Number of buys
-
9
-
Number of sells
-
-5
-
Price
-
$7.20
Significant Holders of Eton Pharmaceuticals, Inc. - Common Stock (ETON) as of Q4 2019
17 filings reported holding ETON - Eton Pharmaceuticals, Inc. - Common Stock as of Q4 2019.
Eton Pharmaceuticals, Inc. - Common Stock (ETON) has 13 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 2,623,150 shares
of 26,828,643 outstanding shares and own 9.8% of the company stock.
Largest 10 shareholders include Opaleye Management Inc. (1,469,456 shares), AWM Investment Company, Inc. (516,882 shares), VANGUARD GROUP INC (281,646 shares), PRELUDE CAPITAL MANAGEMENT, LLC (127,964 shares), BlackRock Inc. (73,810 shares), ROYAL BANK OF CANADA (64,217 shares), Centric Wealth Management (28,000 shares), FIRST TRUST ADVISORS LP (24,168 shares), NORTHERN TRUST CORP (21,393 shares), and WELLS FARGO & COMPANY/MN (6,000 shares).
This table shows the top 13 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.